Division of Hematology and Oncology, Department of Pediatrics, University of Michigan, Ann Arbor, MI.
Blood Research Institute, Blood Center of Wisconsin, Milwaukee, WI.
Blood Adv. 2019 Sep 24;3(18):2748-2750. doi: 10.1182/bloodadvances.2019000656.
Type 3 von Willebrand disease with alloantibodies is a rare clinical entity with few treatment options. Emicizumab prophylaxis in such patients may result in improved hemarthrosis control, lower cost, and enhanced quality of life.
3 型血管性血友病伴同种抗体是一种罕见的临床病症，治疗选择有限。此类患者接受emicizumab 预防治疗可能会改善关节积血控制、降低成本并提高生活质量。
